The Spectacular Rise and Fall of 23andMe

The Spectacular Rise and Fall of 23andMe

23andMe soared with DNA test kits, hitting a $6B valuation in 2021. But a one-time purchase model, failed drug development, and a data breach led to a 98% stock drop, layoffs, and bankruptcy. Can it recover?

In the late 2000s, 23andMe was a Silicon Valley darling, revolutionizing consumer DNA testing. Its saliva kits, once priced at $999, offered insights into ancestry and health risks, sparking a viral craze by 2019. Celebrities like Oprah Winfrey, Eva Langoria and Snoop Dog amplified its hype, and by 2021, the company went public with a 6 billion valuation.

Co-founder Anne Wojcicki’s vision was bold: empower people with genetic data and leverage it for drug development. Yet, by 2025, 23andMe filed for bankruptcy, its stock plummeting 98% from $17.65 to under $1. What went wrong?

The core issue was its business model. DNA tests are a one-time purchase, limiting recurring revenue. A subscription service for health reports, priced at $200 initially, didn’t catch on. Wojcicki pivoted to drug development, building a 150-person team to mine the company’s vast genetic database. A $300 million deal with GSK fueled ambitions, but only two of 50 drug candidates reached early trials. Developing drugs is costly and slow, and 23andMe spread itself thin, unlike focused biotech startups.

Financial strain mounted. The company reported a $667 million loss in its last fiscal year, with revenue dropping to $44.1 million in Q2 2025. Cash reserves dwindled from $216 million to $127 million by late 2024. Layoffs hit hard—40% of staff (200 employees) were cut in November 2024, and the therapeutics division was shuttered. A 2023 data breach affecting 6.9 million users and a class-action lawsuit further eroded trust. All independent board members resigned in September 2024, citing strategic disagreements with Wojcicki, who stepped down as CEO in March 2025. Regeneron acquired 23andMe’s assets for $256 million, a fraction of its peak value.

The lesson? Hype and virality aren’t enough. As Rolfe Winkler noted on The Journal podcast, 23andMe’s story mirrors Silicon Valley’s boom-and-bust cycle. Without a sustainable profit model, even a charismatic leader and a massive database couldn’t save it. Yet, its genetic data remains valuable. Regeneron’s purchase signals potential for future innovation if privacy concerns are addressed.